Блог XT

Ticker Briefing: LLY/USDT — When Volume Climbs and Prices Fall Together

Ticker Briefing: LLY/USDT — When Volume Climbs and Prices Fall Together

2026-11-16

Eli Lilly reported third quarter 2026 revenue of $24,397 million on 29 October 2026, up 39% from a year earlier. That headline figure hides two movements pulling in opposite directions: volume rose 53% while realised prices, what Lilly actually receives per unit, fell 15%.

Lilly is shipping far more medicine than a year ago, but is paid less for each unit.

XT TradFi series banner: a dotted grey world map on a dark grid background, with the XT logo in a green circle beside the TRADFI wordmark.

Why It Matters

Much of Lilly’s scale comes from a narrow base. Mounjaro and Zepbound are one molecule, tirzepatide, sold under two names for different approved uses. The company shows what happens when a medicine moves from specialist prescribing to population volumes.

Lilly also does not fully set its prices. Revenue passes through insurers, rebate arrangements and national reimbursement systems, where price is set by negotiation and legislation, not by demand alone.

The Big Picture

This growth is a manufacturing challenge as much as a commercial one. US revenue rose 34% to $15.1 billion on a 41% volume increase, while revenue outside the US rose 47% to $9.3 billion on a 76% volume increase. Lilly states that its facility investments “have increased our capital expenditures and will result in higher capital expenditures in the near term.” The plants have to exist before the volume does.

By The Numbers

  • $24,397 million: third quarter 2026 revenue, up 39% year on year.
  • $10,723 million and $5,352 million: Mounjaro (up 65%) and Zepbound (up 49%), together roughly 66% of quarterly revenue, calculated against the reported total.
  • Approximately $900 million: one-off benefits, principally $410 million of Jardiance milestones, where Lilly notes that “no further milestones remain,” plus favourable rebate and discount adjustments.
  • $4.2 billion: acquired in-process research and development charges, equal to $4.57 per share against $0.71 a year earlier.
  • $91.0 billion to $92.0 billion: full-year revenue guidance, raised by $5.5 billion at the midpoint, with earnings per share guided to $35.00 to $36.00 on roughly 894 million shares.
  • $184 million: Foundayo, Lilly’s oral GLP-1, in the quarter, with $281 million year to date.
  • August 2023 and January 2026: Inflation Reduction Act selections by the US Department of Health and Human Services: Jardiance effective 2026, Trulicity and Verzenio effective 2028.

What Moves It

The split between volume and price matters most. Realised prices fell 7% in the US and 29% outside it. Lilly attributes the international decline mainly to Mounjaro’s addition to China’s National Reimbursement Drug List, which trades price per unit for a far larger covered population.

One-off items also distort the comparison: growth containing benefits that will not repeat is not comparable to growth without them.

Deal accounting explains the guidance. The acquired in-process research and development charge is why Lilly could raise revenue guidance at the midpoint, lift underlying non-GAAP earnings guidance by $4.07, and still move the earnings per share range down. Reported earnings and operating performance diverged for an accounting reason.

Policy is another driver. Under the Inflation Reduction Act, the US government selects drugs for price negotiation, and Lilly expects more of its own to be chosen: “given our product portfolio, we expect other significant products will be selected in future years.” Its filing adds that tariff exemptions covering the company and pharmaceuticals “may expire, may be terminated or may not apply to any future tariffs.”

Supply integrity comes last. Lilly reports continuing “production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins,” and during the quarter called on platforms, payment companies and regulators to shut down an illegal retatrutide market.

How It Tends To Behave

Drug news does not wait for quarterly results. Lilly’s third-quarter release alone lists US Food and Drug Administration approvals of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes and of Inluriyo with Verzenio in a defined advanced breast cancer population, plus an expanded Jaypirca indication. None came with a revenue figure attached, but each changed what the company can sell.

For Crypto Traders

A market referencing Lilly can therefore reprice on a trial result or a regulatory decision with no financial statement in sight. Not all of these are scheduled. Regulatory decisions come from agencies such as the FDA; trial results are usually announced by the company itself, often on a timetable guided only loosely in advance.

Funding, a periodic payment between longs and shorts, is a holding cost or credit. Leverage, liquidity and liquidation characteristics belong to the contract, not the company.

On XT

LLY/USDT is a USDT margined perpetual futures contract on XT, where LLY references Eli Lilly and Company, headquartered in Indianapolis and listed on the New York Stock Exchange. The contract is cash settled in USDT and confers no shareholding, no dividend entitlement, no voting right and no custody of any share.

The Calendar Lilly Does Not Control

The next quarterly report is the first test of the guided revenue and earnings ranges.

Pipeline news runs on its own clock. Lilly reported positive topline Phase 3 results for retatrutide against Ozempic 2 mg in type 2 diabetes, and said Phase 3 trials of EloraTZP in obesity and type 2 diabetes would begin in the fourth quarter of 2026.

Future Inflation Reduction Act selections and tariff decisions are unresolved, as is Lilly’s patent case against Cipla over generic Verzenio, filed in June 2026 with trial set for May 2028. Nothing above is a forecast.

About XT Exchange

Founded in 2018, XT Exchange is a global digital asset trading platform serving more than 12 million registered users across over 200 countries and regions. Its services span spot, margin and futures trading, TradFi market exposure, a real-world asset marketplace, and everyday payments through XT Pay. Guided by Xplore Crypto Trade with Trust, XT Exchange enters its ninth year with Build the NeXT, reflecting its focus on trust, broader market access, and practical uses for digital assets.

Join the XT Exchange Community: X (Twitter) | Telegram | Facebook | Instagram | LinkedIn | Medium | YouTube

Disclaimer: XT Exchange reserves the right, at its sole discretion, to modify, amend, or cancel this announcement at any time for any reason without prior notice.

Поделиться публикацией
🔍
guide
Зарегистрируйтесь бесплатно и начните свой путь в мире криптовалют.